Editor’s Note: In observance of Labor Day, we will not publish Wealthy Retirement on Monday. Following tomorrow’s weekly recap, the next issue of Wealthy Retirement will come out on Tuesday.
The entire Oxford Club team wishes you a memorable and enjoyable holiday weekend with friends and family.
– James Ogletree, Senior Managing Editor
“Buy low, sell high.”
It’s one of the most basic principles of investing.
So it may come as a bit of a surprise that Chief Income Strategist Marc Lichtenfeld is such a big fan of Moderna (Nasdaq: MRNA) right after it recorded the largest single-day move by an S&P 500 stock in at least a quarter-century.
As you’ll see in Marc’s latest monthly interview with our friends at MarketBeat, he named Moderna his #1 biotech stock to own for the short term.
Marc covered a lot of ground during the interview, including the groundbreaking announcement that sent Moderna and Merck (NYSE: MRK) soaring, why the biotech/healthcare space has been in the news lately, and why healthcare tends to be a strong sector during periods of rising interest rates.
(By the way, he’s too humble to brag about it, so I’ll brag about it for him: On August 19, the day of the Moderna-Merck announcement, Marc closed out his position in Merck in his Technical Pattern Profits trading service for gains of 18% on the stock and 204% on the options… in just a month and a half!)
However, the majority of the interview was devoted to Marc’s favorite healthcare stocks to own for the short, medium, and long term:
- Short term: Moderna, because of a “very bullish” pattern in its chart that Marc believes could quickly propel it another 50 to 100 points higher
- Medium term: a strong acquisition candidate with important clinical trial data scheduled to be released by the end of the quarter
- Long term: a dividend-paying drug giant that Marc calls his “favorite name in healthcare.”
To hear Marc’s full remarks on the healthcare sector and get the names and tickers of all three stocks, click the image above.